ICU Medical (NASDAQ:ICUI) Issues Earnings Results, Beats Estimates By $0.23 EPS

ICU Medical (NASDAQ:ICUI) posted its quarterly earnings results on Thursday. The medical instruments supplier reported $1.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.68 by $0.23, FiscalAI reports. The firm had revenue of $535.94 million during the quarter, compared to the consensus estimate of $541.20 million. ICU Medical had a positive return on equity of 7.71% and a negative net margin of 0.32%. ICU Medical updated its FY 2026 guidance to 7.750-8.450 EPS.

ICU Medical Stock Down 1.2%

ICUI traded down $1.89 during trading hours on Thursday, reaching $149.74. 550,379 shares of the stock traded hands, compared to its average volume of 262,656. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $164.35. The company has a market cap of $3.70 billion, a price-to-earnings ratio of -483.02 and a beta of 0.79. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.45 and a quick ratio of 1.19. The firm’s fifty day simple moving average is $149.17 and its two-hundred day simple moving average is $135.59.

Institutional Trading of ICU Medical

Several large investors have recently modified their holdings of the business. Corient Private Wealth LLC lifted its stake in shares of ICU Medical by 1,299.9% in the fourth quarter. Corient Private Wealth LLC now owns 56,822 shares of the medical instruments supplier’s stock worth $8,107,000 after acquiring an additional 52,763 shares in the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in ICU Medical by 89.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 4,815 shares of the medical instruments supplier’s stock worth $687,000 after purchasing an additional 2,280 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of ICU Medical in the 4th quarter valued at approximately $634,000. Mackenzie Financial Corp purchased a new position in shares of ICU Medical during the 4th quarter valued at approximately $219,000. Finally, XTX Topco Ltd acquired a new stake in shares of ICU Medical during the fourth quarter worth approximately $511,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ICUI. KeyCorp lifted their price objective on ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Piper Sandler increased their price objective on shares of ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Sunday. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $175.67.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.